Biofrontera AG is a biopharmaceutical firm focused on the research, development, and commercialization of dermatological therapies. Its core product line includes Ameluz and the BF-RhodoLED lamp, designed for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing aggressive squamous cell carcinoma. The company's pipeline also features RhodoLED XL for widespread skin lesions, Belixos – a sophisticated cosmetic specifically for irritated and sensitive skin, and Xepi, an agent in development to combat antibiotic-resistant bacterial infections.